MedTrace Logo

Study to Evaluate Using Nelfinavir With Chemoradiation for Non-small Cell Lung Cancer

NCT00791336 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2017-07-28

Study results available
· View outcomes & findings →

Summary

This study combines nelfinavir (NFV) with radiation therapy and chemotherapy as a treatment for non-small cell lung cancer (NSCLC) who are considered candidates for pre-operative treatment.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Nelfinavir

1250 mg twice daily starting for approximately 6.5 weeks.

Sponsors & Collaborators

  • University of Iowa

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2011-03-31
Completion
2011-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00791336 on ClinicalTrials.gov